One of the most paradoxical findings in geriatric medicine is that the same patients losing calcium from their bones are depositing it into their arteries. Postmenopausal women with severe osteoporosis frequently show extensive vascular calcification on imaging — calcium leaving the skeleton where it belongs and accumulating in the aortic wall where it doesn’t. This isn’t coincidence. Both processes share a common upstream regulator: the vitamin K-dependent carboxylation of two specific proteins, Matrix Gla Protein (MGP) and osteocalcin. When K2 status is inadequate, these proteins remain inactive, and calcium trafficking goes haywire.
What Is Vitamin K2?
Vitamin K is a family of fat-soluble naphthoquinones divided into two main forms: K1 (phylloquinone) found in leafy greens, and K2 (menaquinones) produced by bacterial fermentation and present in fermented foods like natto, hard cheeses, and certain animal products. The menaquinones are designated MK-n based on the length of their isoprenoid side chain, with MK-4 and MK-7 being the most studied.[1]
While K1 is preferentially used by the liver to activate clotting factors, K2 — particularly MK-7 with its long 13-hour half-life — is the form that reaches extrahepatic tissues including the vascular wall, bone, and kidneys. This tissue distribution explains why K1 supplementation does little for arterial or skeletal health while K2 demonstrates measurable effects on both.[2]
How Vitamin K2 Works
Gamma-Glutamyl Carboxylation: The fundamental biochemical action of all vitamin K forms is to serve as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that converts specific glutamic acid residues into gamma-carboxyglutamic acid (Gla) residues on target proteins. This carboxylation creates calcium-binding sites — without it, Gla proteins cannot bind calcium and remain functionally inert.[1]
Matrix Gla Protein Activation: MGP is a small 84-amino-acid protein expressed by vascular smooth muscle cells and chondrocytes. In its fully carboxylated form (cMGP), it binds calcium ions and crystals at sites of incipient vascular calcification, sequestering them and preventing hydroxyapatite formation in the arterial intima and media. Uncarboxylated MGP (ucMGP) — the form circulating in K2-deficient individuals — cannot perform this function, and elevated plasma ucMGP is now a validated biomarker of vascular K2 insufficiency.[3]
Osteocalcin Activation in Bone: Osteocalcin is the second major Gla protein, secreted by osteoblasts and constituting the most abundant non-collagenous protein in bone matrix. When carboxylated, osteocalcin binds calcium and hydroxyapatite, integrating mineral into the bone matrix during formation. Uncarboxylated osteocalcin (ucOC) cannot effectively bind calcium, leading to impaired mineralization despite adequate calcium intake.[4]
The Vitamin K Cycle: After carboxylation, vitamin K is oxidized to vitamin K epoxide and must be recycled by vitamin K epoxide reductase (VKOR) — the same enzyme inhibited by warfarin. This is mechanistically why warfarin therapy accelerates both arterial calcification and bone loss: it blocks regeneration of active K2 needed to carboxylate MGP and osteocalcin.[3]
Clinical Evidence
The Rotterdam Study: The landmark Rotterdam Study followed 4,807 subjects for 7-10 years and found that the highest tertile of dietary K2 intake was associated with a 50% reduction in arterial calcification, a 50% reduction in cardiovascular mortality, and a 25% reduction in all-cause mortality compared to the lowest tertile. K1 intake showed no such association — a finding that fundamentally reshaped how researchers think about vitamin K subtypes.[2]
MK-7 Supplementation and Arterial Stiffness: A three-year double-blind, randomized, placebo-controlled trial in 244 postmenopausal women published in Thrombosis and Haemostasis demonstrated that 180 mcg/day of MK-7 significantly decreased carotid artery stiffness as measured by pulse wave velocity, while the placebo group showed progression. The treatment group also showed reductions in circulating uncarboxylated MGP, confirming the proposed mechanism of action.[5]
Bone Mineral Density: The same three-year trial demonstrated that MK-7 supplementation preserved bone mineral density at the lumbar spine and femoral neck and improved bone strength indices compared to placebo. Importantly, bone fracture risk reduction with K2 appears to occur at doses well below those needed to affect coagulation parameters, indicating selective extrahepatic activity.[5]
The PREVEND Cohort: Analysis of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study found that high circulating dehydrocarboxylated MGP — indicating poor vitamin K status — was independently associated with cardiovascular events and all-cause mortality, particularly in patients with chronic kidney disease, hypertension, and diabetes. This biomarker work strengthened the causal interpretation of earlier dietary studies.[3]
Resolving the Calcium Paradox
The clinical observation that aging adults simultaneously lose bone mineral and gain vascular calcium has long puzzled clinicians. Calcium supplementation alone — without addressing the trafficking machinery — has been associated in several meta-analyses with increased cardiovascular events, presumably because supplemental calcium delivered to a system with inactive MGP preferentially deposits in vascular tissue.
The vitamin K2 model offers a unified explanation: when MGP and osteocalcin are properly carboxylated, calcium is actively excluded from the arterial wall and integrated into the bone matrix. When they are not, calcium homeostasis becomes dysregulated in a tissue-specific way — out of bone, into arteries. This conceptual framework has driven the increasing clinical practice of pairing calcium and vitamin D supplementation with K2 to ensure that mineralization occurs at the correct anatomical site.
Safety Profile
Vitamin K2, particularly MK-7, has a remarkably favorable safety profile. Unlike vitamin K1, MK-7 has not been shown to alter prothrombin time or INR at supplemental doses up to 360 mcg/day in healthy individuals. No upper tolerable intake level has been established because no toxicity has been demonstrated even at high doses in long-term human studies.
The major clinical caution involves patients on warfarin or other vitamin K antagonist anticoagulants, where any vitamin K supplementation can interfere with anticoagulation control. For these patients, K2 supplementation should be coordinated with the prescribing physician and accompanied by INR monitoring. Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban do not interact with vitamin K and may be preferable in patients who would benefit from K2 for vascular and bone protection.
Vitamin K2 vs Other Approaches
Versus Bisphosphonates: Bisphosphonates reduce fracture risk by inhibiting osteoclast activity but do nothing for arterial calcification and have been associated in some analyses with paradoxical vascular calcium accumulation. K2 addresses both compartments simultaneously through different molecular targets.
Versus Statins: Statins reduce cardiovascular events primarily through LDL reduction and plaque stabilization but do not directly affect the calcification process. Some evidence suggests statins may even modestly inhibit GGCX, potentially worsening K2-dependent processes — an interaction worth monitoring as research evolves.
MK-4 Versus MK-7: MK-4 has a half-life of only 1-2 hours, requiring multiple daily doses (typically 45 mg total) to maintain steady-state activity, and most clinical trials at this dose have been conducted in Japan. MK-7 has a 72-hour half-life, achieves steady-state plasma concentrations with once-daily dosing in the 90-360 mcg range, and has the strongest cardiovascular evidence base. For most clinical applications, MK-7 is the preferred form.
Dietary Versus Supplemental: Natto contains the highest concentration of MK-7 of any food (approximately 1000 mcg per 100g), but most Western diets provide less than 30 mcg/day of total K2 — well below the 180-360 mcg shown effective in clinical trials. Supplementation is generally required to reach research-validated intake levels in non-natto-consuming populations.
References
- Schurgers LJ, Vermeer C. “Differential lipoprotein transport pathways of K-vitamins in healthy subjects.” Biochimica et Biophysica Acta. 2002;1570(1):27-32.
- Geleijnse JM, Vermeer C, Grobbee DE, et al. “Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study.” Journal of Nutrition. 2004;134(11):3100-3105.
- Schurgers LJ, Cranenburg EC, Vermeer C. “Matrix Gla-protein: the calcification inhibitor in need of vitamin K.” Thrombosis and Haemostasis. 2008;100(4):593-603.
- Booth SL. “Roles for vitamin K beyond coagulation.” Annual Review of Nutrition. 2009;29:89-110.
- Knapen MH, Braam LA, Drummen NE, et al. “Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial.” Thrombosis and Haemostasis. 2015;113(5):1135-1144.
